- Home
- KPRX vs SPPL Comparison
KPRX vs SPPL Comparison
Compare KPRX & SPPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- SPPL
- Stock Information
- Founded
- KPRX 1998
- SPPL 2016
- Country
- KPRX United States
- SPPL Singapore
- Employees
- KPRX N/A
- SPPL N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SPPL
- Sector
- KPRX Health Care
- SPPL
- Exchange
- KPRX Nasdaq
- SPPL Nasdaq
- Market Cap
- KPRX 9.2M
- SPPL 9.8M
- IPO Year
- KPRX N/A
- SPPL 2023
- Fundamental
- Price
- KPRX $2.75
- SPPL $5.62
- Analyst Decision
- KPRX Strong Buy
- SPPL
- Analyst Count
- KPRX 1
- SPPL 0
- Target Price
- KPRX $10.00
- SPPL N/A
- AVG Volume (30 Days)
- KPRX 35.6K
- SPPL 29.0K
- Earning Date
- KPRX 11-07-2025
- SPPL 01-01-0001
- Dividend Yield
- KPRX N/A
- SPPL N/A
- EPS Growth
- KPRX N/A
- SPPL N/A
- EPS
- KPRX N/A
- SPPL N/A
- Revenue
- KPRX N/A
- SPPL $2,764,846.00
- Revenue This Year
- KPRX N/A
- SPPL N/A
- Revenue Next Year
- KPRX N/A
- SPPL N/A
- P/E Ratio
- KPRX N/A
- SPPL N/A
- Revenue Growth
- KPRX N/A
- SPPL N/A
- 52 Week Low
- KPRX $2.25
- SPPL $2.16
- 52 Week High
- KPRX $4.18
- SPPL $16.80
- Technical
- Relative Strength Index (RSI)
- KPRX 55.26
- SPPL 59.56
- Support Level
- KPRX $2.67
- SPPL $5.22
- Resistance Level
- KPRX $2.89
- SPPL $5.79
- Average True Range (ATR)
- KPRX 0.11
- SPPL 0.48
- MACD
- KPRX 0.02
- SPPL -0.09
- Stochastic Oscillator
- KPRX 70.26
- SPPL 44.21
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.